Tirzepatide reduces HF events in patients with HFpEF and obesity
AHA 2024 - Milton Packer shares the results of the SUMMIT trial, in which the efficacy of the dual GIP/GLP-1RA tirzepatide was examined in patients with HFpEF and obesity. He says: “This is really very exciting news and information. We think it would change the practice of how these patients are treated in the future.”
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Gautam Nayak, MD
Frederick Ruberg, MD
Michelle Kittleson, MD, PhD
Frederick Ruberg, MD
